Guardant Health News and Activities

Guardant Health is a company listed under the stock ticker GH (US).

View the org chart displaying its 31 main executives

Most searched biographies at Guardant Health

• Helmy Eltoukhy, Chairman of the Board and Co-Chief Executive Offic...
• Vijaya Gadde, Director
• Steve Krognes, Director

Popular executive movements at Guardant Health

• Craig Eagle, Chief Medical Officer, will leave the company on May 8, 2026  (posted on April 28 2026).
• Matthew Ellis, Senior Vice President, Clinical Development Precision Oncology, has left the company  (posted on December 18 2025).
• Alex Azar has joined the company as Director  (posted on September 16 2025).

Create your alert
to follow the executive moves at Guardant Health.

Guardant Health has 3,511 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).

Popular M&A news in Healthcare

• Adaptive Innovations has just announced a $50 Million fundraising (posted on June 4 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Freeman Health System has acquired Northwest Health (posted on June 2 2026).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board at Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer at Royalty Pharma

Learn more about the Healthcare industry

Press releases by Guardant Health

• American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
• Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
• FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
• Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
• Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
• Guardant Health to Participate in Upcoming Investor Conferences
• Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
• Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
• View more press releases Close

Social media about Guardant Health

• Guardant Health on Wikipedia, Google News & Yahoo Finance
• Guardant Health on LinkedIn, X (Twitter) & YouTube